ISSN 0924-9338
183 papers in the library · 407 citations · publishing 1992-2026
European Psychiatry June 23, 2026 Maximilian Preiß, Valentin Popper, Luna Helene Charlotte Faber et al.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
European Psychiatry June 1, 2026 E. E. Nikolaev, F. V. Orlov, H. Kumar
Introduction Sleep paralysis as a form of parasomnia is associated with poor sleep habits and perceived poor sleep quality (Duarte et al., 2023). Its prevalence in medical students ranges from 16% (Penn et al., 1981) up to 41% (Duarte et al., 2023) with 70% of females reporting experiencing sleep paralysis (Muzammil et al., 2023). Although this disorder does not necessarily testify to the...
European Psychiatry June 1, 2026 G. Smagin, J. Tripp
Introduction MM120 (lysergide D-tartrate, a formulation of LSD) is under development as a potential treatment for generalized anxiety and major depressive disorders. How psychedelic drugs interact at the TrkB receptor, a key target of neuroplasticity, is not reported. Objectives The study evaluated binding and functional activity of known serotonergic psychedelic compounds and SRI fluoxetine at...
European Psychiatry June 1, 2026 H. C. Zhang
Introduction Background: Individuals in the recovery phase of schizophrenia often face persistent challenges including residual symptoms, emotional dysregulation, cognitive deficits, and high relapse rates. Mindfulness-Based Cognitive Therapy (MBCT), effective in mood disorders, shows promise as an adjunctive intervention but requires rigorous evaluation in schizophrenia recovery.Background:...
European Psychiatry June 1, 2026 Eduard Vieta, Bernhard T Baune, N. Cardoner et al.
Introduction Treatment-resistant depression (TRD), a persistent condition impacting up to 30% of patients with major depressive disorder, carries substantial personal and economic burden. There remains an unmet need for therapies that provide both rapid and durable improvements in TRD. Preliminary clinical trials indicate that GH001, a synthetic, inhalable formulation of mebufotenin, has the...
European Psychiatry June 1, 2026 L. Zeng, Y. Chen, Y. Liu et al.
Introduction Current antidepressants (SSRIs/SNRIs) face limitations including delayed onset (4–6 weeks) and modest efficacy (~50% response rates), while serotonergic psychedelics show rapid antidepressant potential via 5-HT2A agonism and synaptic plasticity but are hindered by hallucinogenic activity and 5-HT2B-mediated cardiotoxicity. Objectives To address these challenges, we characterize...
European Psychiatry June 1, 2026 M. Rocha, V. Sharma, S. Prasad et al.
Introduction Psychedelic-assisted psychotherapy has re-emerged as a frontier of psychiatry, offering transformative potential for conditions resistant to conventional treatment. Personality disorders—particularly Borderline Personality Disorder (BPD)—are marked by affective instability, interpersonal dysfunction, and maladaptive relational patterns that often limit therapeutic progress. MDMA’s...
European Psychiatry June 1, 2026 Michał Pastuszak, Katarzyna Jakuszkowiak‐wojten, Maria Gałuszko‐węgielnik et al.
Introduction Research on psychedelic compounds has grown quickly in the past decade. Yet molecule-specific, quantitative summaries are scattered, making it hard to see how interest differs by compound or over time. Objectives To quantify PubMed-indexed publications on ketamine, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), psilocybin, and psilocin; to describe annual trends...
European Psychiatry June 1, 2026
Introduction Treatment-resistant depression (TRD) represents a major challenge in psychiatry. Nearly one-third of patients with major depressive disorder fail to achieve remission despite adequate antidepressant therapy, and about 30% attempt suicide during their lifetime. Given this elevated risk, identifying treatments that rapidly reduce depressive symptoms and suicidality while improving...
European Psychiatry June 1, 2026 N. Northover, S. Kolloju, N. Ibrahim et al.
Introduction Aphantasia, the inability to voluntarily generate mental visual images, may influence emotional processing and memory encoding. While its effects on memory and cognition have been studied, its role in traumatic memory and PTSD remains underexplored. Understanding how aphantasia interacts with PTSD, depression, and social phobia is crucial, underscoring the need for further...
European Psychiatry June 1, 2026 V. Fournier, André Kuntz, Rafik Bouzegaou et al.
Introduction As the number of treatment resistant patient in the psychiatric field has been growing over the last decades, there is a clear need for new therapeutic options. Over several years, the field of psychedelic assisted psychotherapy has been rapidly developing. In this scope ketamine assisted psychotherapy (KAP) has come into psychiatric use to treat depression resistant depression,...
European Psychiatry June 1, 2026 E. Peters, A. Al Hasani, K. Shukla et al.
Introduction Ketamine therapy for treatment-resistant depression has a well-established rapid antidepressant effect for acute symptom management. However, there is far less research on the efficacy of long-term maintenance therapy for relapse prevention. Objectives To examine the utility of long-term maintenance therapy with ketamine infusions delivered in a naturalistic treatment setting....
European Psychiatry June 1, 2026 N. Aguayo-Verdugo, N. Ulloa-Chamblás, R. Zúñiga-Tapia et al.
Introduction University students, particularly in health-related fields, face rising levels of stress, anxiety, and depression, which negatively affect academic performance, social engagement, and overall well-being. Post-pandemic challenges, such as social isolation, uncertainty, and abrupt transitions to online learning, have exacerbated these issues. Mindfulness-based interventions (MBIs)...
European Psychiatry June 1, 2026 R. Szegedi, F. Mónus, Á. Bernáth et al.
Introduction Eco-anxiety—though not a formal diagnosis—captures climate-related distress overlapping with anxiety-spectrum processes. While mindfulness is often framed as protective, facet-level links to eco-anxiety are underexplored in Central/Eastern Europe. Ecological connectedness may also heighten sensitivity to environmental threat. We examined how mindfulness facets and nature...
European Psychiatry June 1, 2026 J. Marta, Â. Ferreira, C. Batista et al.
Introduction Treatment-Resistant Depression (TRD) is a major clinical challenge, affecting about 30% of patients with major depressive disorder. It is associated with high morbidity and mortality, reflected in increased suicide risk, hospitalizations, and impaired quality of life. Electroconvulsive Therapy (ECT) remains the therapeutic gold standard, particularly in severe cases with psychotic...
European Psychiatry June 1, 2026 A. Arshad, A. Khalid, M. Bilal et al.
Introduction Dissociative fugue is a rare condition, falling within the spectrum of dissociative identity disorders as per the DSM-V criteria. This condition is marked by an abrupt and unforeseen departure from one’s usual routine, accompanied by memory lapses. Its occurrence within the general population is estimated at a mere 0.2%, and individuals may linger in this fugue state for a few days...
European Psychiatry June 1, 2026 N. Ayad, S. Makhoul, F. Alkhaja
Introduction Treatment-resistant depression remains a major clinical challenge, with many patients experiencing relapse despite advances in medication and psychotherapy. Esketamine offers rapid relief from depressive symptoms, while psychotherapy helps patients build lasting skills to manage their condition. Despite their individual effectiveness, little is known about how these treatments work...
European Psychiatry June 1, 2026 A. Rami
Introduction Suicidal crisis represents a major psychiatric emergency, often occurring in the context of mood disorders and requiring rapid, effective interventions. Traditional antidepressant treatments usually have a delayed onset of action, underscoring the need for fast-acting therapeutic alternatives. In recent years, ketamine—an NMDA receptor antagonist—has emerged as a promising option...
European Psychiatry June 1, 2026 V. Sharma, S. Ather, A. Sič et al.
Introduction Suicide is a leading cause of death in the psychiatric population. The existing modes of treatment (pharmacological and psychotherapeutic) for suicidality are effective but have longer onset, this delay causing a dangerous therapeutic gap in an acute crisis. We compare the two fast-acting treatments, the newer psychopharmacological agent Ketamine and well-established...
European Psychiatry June 1, 2026 V. Martiadis, F. Raffone, S. Testa et al.
Introduction Treatment-resistant depression (TRD) is a severe condition associated with high suicide risk and limited response to conventional antidepressants. Intranasal esketamine has shown rapid efficacy in reducing depressive symptoms and suicidal ideation. Objectives This observational study assessed the real-world effectiveness of esketamine in reducing suicidal ideation, self-harm...
European Psychiatry June 1, 2026 J. García Jiménez, S. Posik, B. Herrejón et al.
Introduction Treatment-resistant depression (TRD) is highly burdensome. Intranasal esketamine is effective, yet hospital-centric delivery adds travel and continuity barriers that may hinder adherence and outcomes. We hypothesize that community outpatient, patient-proximal delivery —often with the patient’s usual psychiatrist—improves effectiveness, engagement and acceptability, consistent with...
European Psychiatry June 1, 2026 I. C. Mândraș, A. L. Comșa
Introduction Suicidality represents a major clinical and public health challenge, particularly among patients with treatment-resistant depression (TRD), who carry a disproportionately high risk of suicide. Traditional antidepressants often have delayed onset and limited efficacy in reducing suicidal ideation in this high-risk population, highlighting the need for rapid-acting interventions....
European Psychiatry June 1, 2026 E. Lo, A. K. C. Chau, A. E. Z. Lian et al.
Introduction Robust evidence supports the co-occurrence of dissociation and psychosis and their subclinical manifestations in both clinical and non-clinical populations. However, it remains unclear whether specific dissociative symptoms are uniquely associated with individual psychotic symptoms, particularly within the positive dimension. The network theory of psychopathology offers a useful...
European Psychiatry June 1, 2026 J. B. French, J. Kar, B. R. Carr
Introduction The psychiatric incorporation of mindfulness has advanced without a parallel precision in definition. Within both clinical and lay discourse, mindfulness is often conflated with meditation broadly, or with forms of contemplation oriented toward ethical or spiritual ends. This conceptual slippage obscures distinct phenomenological structures and risks importing unexamined...
European Psychiatry June 1, 2026 W. Aldulaimy, A. Shah
Introduction TBI patients often suffer from severe, treatment-resistant depression and PTSD. Ketamine shows promise in non-TBI populations, but its efficacy in TBI patients needs exploration for efficacy and tolerability. Objectives Evaluate ketamine’s clinical effectiveness and safety (PHQ-9, GAD-7, PCL-5 scores) in post-TBI patients, comparing IM, intranasal, and oral routes. Methods Design:...